-
公开(公告)号：US07488498B2
公开(公告)日：2009-02-10
申请号：US11246453
申请日：2005-10-11
申请人： Chisato Makino , Nobutaka Ninomiya , Haruo Orita , Hidetoshi Sakai , Akira Yabuki , Nobuo Kato , Shigeru Shioya
发明人： Chisato Makino , Nobutaka Ninomiya , Haruo Orita , Hidetoshi Sakai , Akira Yabuki , Nobuo Kato , Shigeru Shioya
CPC分类号： A61K9/0095 , A61K9/146 , A61K9/1617 , A61K9/1647 , A61K9/1652 , A61K9/2054 , A61K9/209 , A61K9/2853 , A61K9/2866 , A61K9/5026 , A61K9/5031 , A61K9/5036 , A61K9/5084 , A61K31/195 , A61K31/198 , A61K45/06 , A61K2300/00
摘要： There is provided a single preparation which directly decreases both of the post prandial blood glucose level and the fasting blood glucose level close to normal levels, by release-sustaining a drug capable of decreasing the post prandial blood glucose level of diabetic patients close to the normal level, or mixing a controlled release drug capable of decreasing the post prandial blood glucose level close to the normal level with an immediate release drug. It is particularly preferable that the drug capable of decreasing the post prandial blood glucose level close to the normal level is nateglinide.
摘要翻译： 提供了一种直接降低餐后血糖水平和接近正常水平的空腹血糖水平的单一制剂，通过释放维持能够降低接近正常的糖尿病患者的餐后血糖水平的药物 或者使用立即释放药物混合能够降低接近正常水平的餐后血糖水平的控释药物。 特别优选能够降低接近正常水平的餐后血糖水平的药物是那格列奈。
-
公开(公告)号：US20060029669A1
公开(公告)日：2006-02-09
申请号：US11246453
申请日：2005-10-11
申请人： Chisato Makino , Nobutaka Ninomiya , Haruo Orita , Hidetoshi Sakai , Akira Yabuki , Nobuo Kato , Shigeru Shioya
发明人： Chisato Makino , Nobutaka Ninomiya , Haruo Orita , Hidetoshi Sakai , Akira Yabuki , Nobuo Kato , Shigeru Shioya
IPC分类号： A61K9/22
CPC分类号： A61K9/0095 , A61K9/146 , A61K9/1617 , A61K9/1647 , A61K9/1652 , A61K9/2054 , A61K9/209 , A61K9/2853 , A61K9/2866 , A61K9/5026 , A61K9/5031 , A61K9/5036 , A61K9/5084 , A61K31/195 , A61K31/198 , A61K45/06 , A61K2300/00
摘要： There is provided a single preparation which directly decreases both of the post prandial blood glucose level and the fasting blood glucose level close to normal levels, by release-sustaining a drug capable of decreasing the post prandial blood glucose level of diabetic patients close to the normal level, or mixing a controlled release drug capable of decreasing the post prandial blood glucose level close to the normal level with an immediate release drug. It is particularly preferable that the drug capable of decreasing the post prandial blood glucose level close to the normal level is nateglinide.
-
公开(公告)号：US07022339B2
公开(公告)日：2006-04-04
申请号：US10183322
申请日：2002-06-28
申请人： Chisato Makino , Nobutaka Ninomiya , Haruo Orita , Hidetoshi Sakai , Akira Yabuki , Nobuo Kato , Shigeru Shioya
发明人： Chisato Makino , Nobutaka Ninomiya , Haruo Orita , Hidetoshi Sakai , Akira Yabuki , Nobuo Kato , Shigeru Shioya
CPC分类号： A61K9/0095 , A61K9/146 , A61K9/1617 , A61K9/1647 , A61K9/1652 , A61K9/2054 , A61K9/209 , A61K9/2853 , A61K9/2866 , A61K9/5026 , A61K9/5031 , A61K9/5036 , A61K9/5084 , A61K31/195 , A61K31/198 , A61K45/06 , A61K2300/00
摘要： There is provided a single preparation which directly decreases both of the post prandial blood glucose level and the fasting blood glucose level close to normal levels, by release-sustaining a drug capable of decreasing the post prandial blood glucose level of diabetic patients close to the normal level, or mixing a controlled release drug capable of decreasing the post prandial blood glucose level close to the normal level with an immediate release drug. It is particularly preferable that the drug capable of decreasing the post prandial blood glucose level close to the normal level is nateglinide.
-
公开(公告)号：US06830759B2
公开(公告)日：2004-12-14
申请号：US10183405
申请日：2002-06-28
申请人： Chisato Makino , Nobutaka Ninomiya , Haruo Orita , Hidetoshi Sakai , Akira Yabuki , Nobuo Kato , Shigeru Shioya
发明人： Chisato Makino , Nobutaka Ninomiya , Haruo Orita , Hidetoshi Sakai , Akira Yabuki , Nobuo Kato , Shigeru Shioya
IPC分类号： A61K920
CPC分类号： A61K31/00 , A61K9/2077 , A61K9/2081 , A61K31/195 , A61K45/06
摘要： There is provided a single preparation which directly decreases both of the post prandial blood glucose level and the fasting blood glucose level close to normal levels, by release-sustaining a drug capable of decreasing the post prandial blood glucose level of diabetic patients close to the normal level, or mixing a controlled release drug capable of decreasing the post prandial blood glucose level close to the normal level with an immediate release drug. It is particularly preferable that the drug capable of decreasing the post prandial blood glucose level close to the normal level is nateglinide, repaglinide, or mitiglinide (KAD-1229).
摘要翻译： 提供了一种直接降低餐后血糖水平和接近正常水平的空腹血糖水平的单一制剂，通过释放维持能够降低接近正常的糖尿病患者的餐后血糖水平的药物 或者使用立即释放药物混合能够降低接近正常水平的餐后血糖水平的控释药物。 特别优选能够降低接近正常水平的餐后血糖水平的药物是那格列奈，瑞格列奈或米格列奈（KAD-1229）。
-
-
-
搜索结果
4 条记录 (耗时 0.012 秒)
